Jennifer B. Green

机构：Merck & Co., Inc., Rahway, NJ, USA (United States), Clinical Research Institute · ORCID：0000-0002-9967-5352

发表论文 174 篇 · 总被引 13412 次 · h-index 44

代表论文

• Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (2025 · New England Journal of Medicine · 被引 255)
• Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) (2025 · Diabetes Care · 被引 13)
• Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis (2025 · The Lancet Diabetes & Endocrinology · 被引 12)
• Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both (2025 · Journal of the American College of Cardiology · 被引 6)
• Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia (2025 · Clinical Journal of the American Society of Nephrology · 被引 6)
• Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial (2025 · Nephrology Dialysis Transplantation · 被引 6)